Last reviewed · How we verify
Pegasys /RBV
Pegasys (peginterferon alfa-2a) is an interferon that activates the immune system to fight viral infections, while ribavirin (RBV) is a nucleoside analog that inhibits viral replication.
Pegasys (peginterferon alfa-2a) is an interferon that activates the immune system to fight viral infections, while ribavirin (RBV) is a nucleoside analog that inhibits viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1-6.
At a glance
| Generic name | Pegasys /RBV |
|---|---|
| Sponsor | Beijing Kawin Technology Share-Holding Co., Ltd. |
| Drug class | Interferon alfa-2a (pegylated) + nucleoside analog combination |
| Target | Interferon-alpha receptor; HCV RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
Pegasys is a pegylated form of interferon alfa-2a that enhances and prolongs immune response against hepatitis C virus by activating natural killer cells and macrophages. Ribavirin works synergistically by inhibiting viral RNA-dependent RNA polymerase and reducing HCV replication. The combination therapy targets multiple steps of the viral lifecycle to achieve sustained virologic response.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1-6
Common side effects
- Fatigue
- Headache
- Myalgia
- Anemia
- Neutropenia
- Depression/mood changes
- Injection site reactions
- Nausea
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (PHASE3)
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital (PHASE4)
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C (PHASE1, PHASE2)
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy (PHASE4)
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegasys /RBV CI brief — competitive landscape report
- Pegasys /RBV updates RSS · CI watch RSS
- Beijing Kawin Technology Share-Holding Co., Ltd. portfolio CI